The Role of Genetic Mutation on Schizophrenia: A Basic Review Prior to Pharmacogenomics

Abstract

A bioinformatic approach is used to identify indications of reposition drug. It drives newer methods to treating schizophrenia by comparing the binding profiles of currently available clinical compounds to targets or groups of targets derived based on genome-wide association studies (GWAS). Here in, we present the molecular expression of schizophrenia due to polymorphism. The study involves papers indexed by Scopus, and the search uses a combination of the following keyword variants; "GWAS" AND "genom" AND schizophrenia, "GWAS" AND "repurposing drug" AND "schizophrenia". This study only used original articles in English peer-reviewed journals published during 2022. Thus, the screening results of sources were narrowed to 5 original articles that met the inclusion criteria. We identified 9 genes involved in pathophysiology of schizophrenia. Interestingly, a number of genes have been discovered as being the druggable target. Publications on drug repurposing for schizophrenia treatment suggest possible medication candidates such as verapamil, cinnarizine, nicotine, varenicline, galantamine, and DPP4 inhibitors metoclopramide, trifluoperazine, and neratinib.